Cargando…
The FGFR1 inhibitor PD173074 induces mesenchymal–epithelial transition through the transcription factor AP-1
BACKGROUND: Epithelial–mesenchymal transition (EMT) is a crucial process in cancer progression that provides cancer cells with the ability to escape from the primary focus, invade stromal tissues and migrate to distant regions. Cell lines that lack E-cadherin show increased tumorigenesis and metasta...
Autores principales: | Nguyen, P T, Tsunematsu, T, Yanagisawa, S, Kudo, Y, Miyauchi, M, Kamata, N, Takata, T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798957/ https://www.ncbi.nlm.nih.gov/pubmed/24045665 http://dx.doi.org/10.1038/bjc.2013.550 |
Ejemplares similares
-
Lysosomal Sequestration Impairs the Activity of the Preclinical FGFR Inhibitor PD173074
por: Englinger, Bernhard, et al.
Publicado: (2018) -
Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer
por: Armstrong, K, et al.
Publicado: (2011) -
TBLR1 is a novel prognostic marker and promotes epithelial–mesenchymal transition in cervical cancer
por: Wang, J, et al.
Publicado: (2014) -
Disabled-2 downregulation promotes epithelial-to-mesenchymal transition
por: Martin, J C, et al.
Publicado: (2010) -
PD173074, a selective FGFR inhibitor, reverses MRP7 (ABCC10)-mediated MDR
por: Anreddy, Nagaraju, et al.
Publicado: (2014)